Saturday, October 31, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 5, 2026

Sampokoncernens resultat för 2025

View original at globenewswire.com
Sampokoncernens resultat för 2025 Sampo Abp, pressmeddelande, 5 februari 2026 kl 8.35 EET Sampokoncernens resultat för 2025 Intäktstillväxten på jämförbar basis uppgick till 8 procent tack vare en stark utveckling inom privatkundsverksamheten och små och medelstora företag i både Norden och Storbritannien.Det valutajus…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Winter conditions in the Nordics were particularly harsh in early 2026, expected to lead to substantially more weather-related claims compared to same period 2025

    80% confidence
  • Price competition increased in the large corporate segment during 2025 and is expected to continue in 2026

    80% confidence
  • Sampo reached its operational target for digital sales in the Nordic private segment one year ahead of schedule

    80% confidence
  • Sampo is well positioned to achieve financial targets and continue creating sustainable value for shareholders in 2026

    80% confidence
  • Previous investments in digital sales and service solutions have been successful

    80% confidence
  • The updated dividend policy ensures a long-term attractive combination of progressive dividend income and share buybacks for investors

    80% confidence
  • Sampo continued to consistently implement its organic growth strategy in 2025, benefiting from scale advantages and unique market position

    80% confidence
  • Potential to supplement internal capital generation with proceeds from divestment of legacy holdings and expansion of partial internal model to Danish operations

    80% confidence
  • Underlying claims costs have returned to long-term average levels in most key markets except Norway where they remain somewhat elevated

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com